Nektar Therapeutics (NKTR) Stock Forecast & Price Target

Nektar Therapeutics is attractive because REZPEG has shown durable, differentiated efficacy across atopic dermatitis and alopecia areata, including 63% 6mo off-treatment SALT ≤20 maintenance after 52wk versus 10% after 36wk, plus sustained EASI benefits through 52wk and meaningful ACQ-5 improvements in patients with comorbid asthma. Its novel Treg-focused mechanism appears to offer a cleaner safety profile than JAK inhibitors, with no increased infection or conjunctivitis signal to date and no expected lab monitoring burden, which could support adoption in two large, underpenetrated markets. The outlook is further supported by a clearer competitive landscape in AD, a Phase 3 ZENITH-AD program with initial topline data expected mid-2028 and BLA submission targeted for 2029, and the removal of litigation uncertainty after a $90M jury award.

Nektar Therapeutics is facing a bearish fundamental setup because the recent REZOLVE-AA selloff exposed investor concern over weaker 36-week off-treatment maintenance, where only 10% of responders maintained SALT ≤20 at six months, even though the company’s planned Phase 3 ZENITH-AA relies on a different 52-week induction regimen. The program still carries meaningful execution risk because efficacy data remain based on small samples, the pipeline is early-stage and concentrated around rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422, and NKTR-255, and the next major catalysts are limited before 2027 and mid-2028. Although 2Q26 cash and investments of $1.02 billion provide runway and the enterprise value fell to about $565 million, the stock can remain pressured by catalyst scarcity, uncertainty around partnership or M&A interest, and ongoing clinical, regulatory, and competitive risks.